Discounted Cash Flow (DCF) Analysis Unlevered

Applied Therapeutics, Inc. (APLT)

$ 10.59
-0.19 (-1.76%)
Stock DCF: - | 10.59 | undervalue

Operating Data

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ---------
Revenue (%)
EBITDA ---------
EBITDA (%)
EBIT ---------
EBIT (%)
Depreciation ---------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Total Cash ---------
Total Cash (%)
Account Receivables ---------
Account Receivables (%)
Inventories ---------
Inventories (%)
Accounts Payable ---------
Accounts Payable (%)
Capital Expenditure ---------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 10.59
Beta 0.911
Diluted Shares Outstanding 22.43
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 5.739
Total Debt 2.81
Total Equity 237.49
Total Capital 240.31
Debt Weighting 1.17
Equity Weighting 98.83
Wacc

Build Up Free Cash

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ---------
EBITDA ---------
EBIT ---------
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT ---------
Depreciation ---------
Accounts Receivable ---------
Inventories ---------
Accounts Payable ---------
Capital Expenditure ---------
UFCF ---------
WACC
PV UFCF ---------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 5.73
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -54.65
Equity Value -
Shares Outstanding 22.43
Equity Value Per Share -